32 citations
,
October 2023 in “Biomedicines” This study found that chronic low-grade inflammation exists independently of excess weight or obesity in women with PCOS, with notable increases in specific cytokines such as IL-9, MCP-3, and MIP-1α.
29 citations
,
September 2023 in “Journal of Clinical Medicine” This study found that semaglutide significantly reduced body weight in almost 80% of obese PCOS patients unresponsive to lifestyle changes, often normalizing menstrual cycles with few side effects.
6 citations
,
August 2023 in “Fertility and Sterility” This review details the 2023 International Guideline update for assessing and managing polycystic ovary syndrome, which provides evidence-based recommendations to improve care and patient outcomes but notes the remaining low to moderate quality of evidence.
2 citations
,
July 2023 in “Frontiers in Endocrinology” This review identified and evaluated polycystic ovary syndrome models of care, finding that only three fully aligned with international guidelines and generally received positive feedback on satisfaction; just one showed an impact on patients' BMI.
1 citations
,
May 2023 in “Cell reports medicine” Sons of mothers with polycystic ovary syndrome (PCOS) have a higher risk of obesity and insulin resistance, possibly due to certain genes and factors passed down from their mothers.
11 citations
,
November 2021 in “The Journal of Clinical Endocrinology and Metabolism” This study found that genetic risk factors for PCOS can lead to nonreproductive phenotypes in men, suggesting these effects are independent of ovarian function.
58 citations
,
November 2020 in “International Journal of Molecular Sciences” This review discusses the relationship between SHBG, NAFLD, and PCOS and reports no new clinical results; the authors highlight low hepatic SHBG production as potentially significant in PCOS pathogenesis.
5 citations
,
July 2020 in “PubMed” This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.
12 citations
,
July 2020 in “DOAJ (DOAJ: Directory of Open Access Journals)” This review evaluates the hormonal, metabolic, and clinical aspects of a male equivalent PCOS syndrome in men and highlights areas where further research is needed, reporting no new empirical findings.
49 citations
,
February 2019 in “The Journal of Clinical Endocrinology and Metabolism” This review offers evidence-based recommendations for diagnosing and treating female pattern hair loss, emphasizing clinical assessment and starting treatment with minoxidil, while noting that measurement of certain hormones and vitamins is optional.
308 citations
,
December 2018 in “PLOS Genetics” This study identified three novel genetic loci associated with PCOS and found similar genetic architecture across different diagnostic criteria, with evidence suggesting genetic links between PCOS and various metabolic and psychological traits.
11 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This letter highlights that levonorgestrel intrauterine devices may lead to fewer systemic side effects, like acne, compared to its oral administration due to lower systemic levels of progestogens.
47 citations
,
June 2016 in “JAMA Dermatology” This study suggests men with early androgenetic alopecia might have hormonal profiles similar to women with polycystic ovarian syndrome, potentially indicating risk for related health complications.
149 citations
,
December 2007 in “The Journal of Clinical Endocrinology and Metabolism” Women with PCOS have overall higher body fat, not abnormal fat placement, and more insulin resistance.
12 citations
,
December 2005 in “PubMed” This study suggests that some men with premature androgenic alopecia may have hormonal profiles similar to women with polycystic ovary syndrome, potentially indicating a male equivalent of the condition.
414 citations
,
August 2005 in “The Journal of Clinical Endocrinology and Metabolism” This study estimates the total cost of evaluating and treating polycystic ovary syndrome in reproductive-aged women in the United States to be $4.36 billion, suggesting more liberal screening could be beneficial.
4809 citations
,
January 2004 in “Fertility and Sterility” This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.